M
Mats Johnson
Researcher at University of Gothenburg
Publications - 63
Citations - 3278
Mats Johnson is an academic researcher from University of Gothenburg. The author has contributed to research in topics: Attention deficit hyperactivity disorder & Medicine. The author has an hindex of 17, co-authored 45 publications receiving 2946 citations. Previous affiliations of Mats Johnson include Sahlgrenska University Hospital & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Computerized Training of Working Memory in Children With ADHD-A Randomized, Controlled Trial
Torkel Klingberg,Elisabeth Fernell,Pernille J. Olesen,Mats Johnson,Per A. Gustafsson,Kerstin Dahlström,Christopher Gillberg,Hans Forssberg,Helena Westerberg +8 more
TL;DR: In this article, the effect of computerized, systematic practice of working memory tasks on children with Attention Deficit/Hyperactivity Disorder (ADHD) has been investigated using a randomized, controlled, double-blind trial.
Journal ArticleDOI
Co-existing disorders in ADHD -- implications for diagnosis and intervention.
Christopher Gillberg,I. C. Gillberg,Peder Rasmussen,Björn Kadesjö,Henrik Soderstrom,Maria Råstam,Mats Johnson,Aribert Rothenberger,Lena Niklasson +8 more
TL;DR: It would not be appropriate to develop ADHD–services where clinicians would only have expertise in ADHD as such, and anyone working with children, adolescents and adults with ADHD would need to have training in general neuropsychiatry.
Journal ArticleDOI
Omega-3/Omega-6 Fatty Acids for Attention Deficit Hyperactivity Disorder A Randomized Placebo-Controlled Trial in Children and Adolescents
TL;DR: A subgroup of children and adolescents with ADHD, characterized by inattention and associated neurodevelopmental disorders, treated with omega 3/6 fatty acids for 6 months responded with meaningful reduction of ADHD symptoms.
Journal ArticleDOI
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder
David Coghill,Tobias Banaschewski,Michel Lecendreux,Cesar Soutullo,Mats Johnson,Alessandro Zuddas,Colleen Anderson,Richard Civil,Nicholas Higgins,Andrew Lyne,Liza Squires +10 more
TL;DR: LDX was effective and generally well tolerated in children and adolescents with ADHD and key secondary efficacy measures were the investigator-rated ADHD-RS-IV and the Clinical Global Impressions-Improvement (CGI-I) rating.
Journal ArticleDOI
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
Philip Hazell,Shuyu Zhang,Tomasz Wolańczyk,Joanne Barton,Mats Johnson,Alessandro Zuddas,Marina Danckaerts,Andrula Ladikos,David Benn,Roni Yoran-Hegesh,Pål Zeiner,David Michelson +11 more
TL;DR: Atomoxetine protects against the relapse of ADHD symptoms regardless of the presence or absence of comorbid ODD, and does not influence the rate of relapse of patients with ADHD during longer-term treatment with atomxetine.